Healthcare · NIFTY 500
Concord Biotech Limited
NSECONCORDBIO
BSE543960 ISININE338H01029 SeriesEQ Listed on NSE · BSE · MSEI
₹601.80 +4.60 (+0.77%) Updated 12 Nov, 8:49 pm IST
Price, daily close-13.03% in a year
Today
- Open
- ₹600.00
- Prev close
- ₹597.20
- Day high
- ₹604.40
- Day low
- ₹595.80
- Volume
- 1.97 L
- Value traded
- ₹11.80 Cr
- Upper circuit
- ₹716.60
- Lower circuit
- ₹477.80
- 52W high
- ₹807.50
- 52W low
- ₹493.50
- 1 month
- -4.93%
- 6 months
- +5.54%
52W low52W high
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Market cap₹6,296 Cr
P/E (TTM)22.53
P/B3.03
Book value / share₹198.42
EPS (TTM)₹26.71
ROE13.6%
Dividend yield1.25%
Dividend (12m)₹7.55 / share
Net margin (TTM)24.1%
Operating margin33.8%
Debt / equity—
Current ratio6.40
EV / EBITDA15.68
Sales growth (YoY qtr)+25.10%
Profit growth (YoY qtr)+11.12%
Sales CAGR 3Y—
Profit CAGR 3Y—
Shares10.46 Cr
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Revenue · QoQ (vs last quarter)
—+32%-32%+44%-21%+76%-53%+21%+12%+17%-21%+20%
Revenue · YoY (vs a year ago)
————+1.4%+35%-5.5%-20%+14%-24%+26%+25%
Net profit · QoQ (vs last quarter)
—+22%-37%-100%—+85%-69%+44%+1.4%+38%-34%+21%
Net profit · YoY (vs a year ago)
————-2.1%+48%-26%—-15%-37%+33%+11%
RevenueNet profitLine = trend
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
EPS (₹) · YoY (vs a year ago)
————-2.0%+48%-26%-34%-16%-37%+31%+10%
EPS (₹)Line = trend
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 | 309 |
| Other income | 8.2 | 10.8 | 10.3 | 10.0 | 14.7 | 9.4 | 13.7 | 13.4 | 10.0 | 15.3 | 12.8 | 10.2 |
| Total income | 249 | 330 | 226 | 320 | 259 | 439 | 218 | 260 | 288 | 341 | 270 | 319 |
| Raw material | 47.4 | 55.7 | 55.0 | 68.1 | 61.0 | 80.3 | 59.9 | 57.3 | 66.6 | 70.5 | 69.9 | 63.7 |
| Purchases | 23.2 | 11.5 | 11.8 | 21.7 | 12.2 | 10.3 | 12.8 | 13.6 | 20.4 | 15.7 | 11.3 | 16.2 |
| Employee cost | 30.7 | 34.0 | 31.7 | 33.7 | 34.6 | 39.0 | 37.9 | 44.5 | 46.8 | 47.8 | 43.6 | 52.3 |
| Other expenses | 57.1 | 61.9 | 54.6 | 63.5 | 59.2 | 72.0 | 59.6 | 65.1 | 66.3 | 74.0 | 77.2 | 78.8 |
| Total expenses | 149 | 199 | 148 | 187 | 160 | 254 | 160 | 177 | 198 | 227 | 193 | 223 |
| Operating profit | 106 | 134 | 81.3 | 137 | 98.0 | 190 | 61.4 | 88.5 | 95.7 | 119 | 82.4 | 104 |
| OPM % | 44.0% | 42.1% | 37.7% | 44.1% | 40.1% | 44.3% | 30.1% | 35.8% | 34.5% | 36.4% | 32.0% | 33.8% |
| Finance cost | 0.5 | 0.5 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Depreciation | 13.5 | 13.7 | 13.2 | 13.3 | 13.3 | 14.6 | 17.8 | 18.4 | 18.7 | 19.5 | 18.1 | 18.4 |
| Exceptional items | — | — | — | — | — | — | — | — | -3.3 | — | — | — |
| Profit before tax | 100 | 131 | 78.2 | 133 | 99.3 | 185 | 57.2 | 83.4 | 86.9 | 114 | 77.1 | 96.1 |
| Tax | 25.5 | 33.7 | 19.9 | 34.6 | 25.2 | 43.2 | 14.7 | 22.6 | 22.5 | 25.6 | 20.6 | 25.9 |
| Net profit | 77.6 | 95.0 | 59.6 | 95.7 | 75.9 | 140 | 44.1 | 63.1 | 63.6 | 88.5 | 57.7 | 69.6 |
| Profit to shareholders | 77.6 | 95.0 | 59.6 | 0.0 | 75.9 | 140 | 44.1 | 63.6 | 64.5 | 88.8 | 58.5 | 70.7 |
| EPS (₹) | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 | 6.03 | 6.08 | 8.46 | 5.52 | 6.65 |
Profit & loss
Results for each year
3 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
FY24
FY25
FY26
Revenue · YoY (vs a year ago)
—+18%-12%
Net profit · YoY (vs a year ago)
—+21%-30%
RevenueOperating profitNet profitLine = trend
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,017 | 1,200 | 1,055 |
| Other income | 33.8 | 44.4 | 52.4 |
| Total expenses | 642 | 749 | 762 |
| Employee cost | 123 | 139 | 177 |
| Operating profit | 432 | 506 | 364 |
| OPM % | 42.4% | 42.2% | 34.5% |
| Finance cost | 2.6 | 0.5 | 0.3 |
| Depreciation | 53.6 | 54.4 | 74.5 |
| Profit before tax | 409 | 496 | 342 |
| Tax | 104 | 123 | 85.4 |
| Tax rate % | 25.5% | 24.8% | 25.0% |
| Net profit | 308 | 372 | 259 |
| Profit to shareholders | 308 | 372 | 261 |
| Net margin % | 30.3% | 31.0% | 24.7% |
| EPS (₹) | 29.45 | 35.52 | 24.78 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Mar 24
Mar 25
Mar 26
Sep 26
Shareholders' equity · YoY (vs a year ago)
—+19%+11%—
Shareholders' equityBorrowingsCashLine = trend
| ₹ Cr | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|
| Shareholders' equity | 1,527 | 1,813 | 2,017 | 2,076 |
| Long-term borrowings | 0.0 | 0.0 | 0.0 | 0.0 |
| Short-term borrowings | 6.2 | 0.4 | 0.0 | 0.0 |
| Total borrowings | 6.2 | 0.4 | — | — |
| Current liabilities | 142 | 184 | 169 | 202 |
| Fixed assets (PPE) | 572 | 792 | 786 | 760 |
| Inventories | 208 | 240 | 326 | 398 |
| Trade receivables | 350 | 522 | 460 | 412 |
| Cash & equivalents | 15.1 | 0.9 | 12.2 | 7.5 |
| Current assets | 896 | 1,135 | 1,250 | 1,291 |
| Total assets | 1,701 | 2,034 | 2,235 | 2,327 |
| Debt / equity | 0.00 | 0.00 | — | — |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
FY24
FY25
FY26
Operations · YoY (vs a year ago)
—-7.9%+9.1%
OperationsInvestingFinancingLine = trend
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash from operations | 265 | 245 | 267 |
| Cash from investing | -155 | -160 | -143 |
| Cash from financing | -99.2 | -98.8 | -113 |
| Spent on fixed assets | -85.7 | -111 | -95.2 |
| Free cash flow | 180 | 133 | 172 |
| Net cash flow | 11.6 | -14.2 | 11.3 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Promoter & groupPublic
Latest (5 Nov 2026)
44.1%promoter
- Promoter & group
- 44.09%
- Public (FIIs, mutual funds, retail…)
- 55.91%
- Promoter change, last quarter
- 0.00 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Bonus 1:1
- Dividend - Rs 7.55 Per Share
- Dividend - Rs 10.70 Per Share
- Dividend - Rs 8.75 Per Share
- Annual General Meeting
Board meetings
- the financial results for the period ended September 30, 2026
- CONCORD BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Fina…
- bonus
- Increase in authorised capital/Bonus.
- the financial results for the period ended Jun 30, 2026
Filings with NSE
- General Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Analysts/Institutional Investor Meet/Con. Call Updates
- Copy of Newspaper Publication
- Investor Presentation
- Record Date
Latest news
Concord Biotech shares fall 5% after bonus issuance approval; board nods authorised capital increase to ₹22 croreUpstox · 23 Sep, 12:30 pmConcord Biotech (NSEI:CONCORDBIO) Stock Forecast & Analyst PredictionsSimply Wall St · 29 Oct, 12:30 pmConcord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each held - CNBC TV18LinkedIn · 23 Sep, 12:30 pmConcord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each heldCNBC TV18 · 23 Sep, 12:30 pmConcord Biotech 1:1 bonus issue announced! Jhunjhunwala family-backed stock up 50% in 6 months- record date, detailsTradingView · 23 Sep, 12:30 pmStock to buy today: Concord Biotech (₹1,513.40) – BUYBusinessLine · 18 Aug, 12:30 pm1:1 Bonus Issue: Concord Biotech announces free shares; check update on record dateZee Business · 23 Sep, 12:30 pmBuzzing Stocks: Max Estates gains 6% on JDA; Concord Biotech rises 4% after bonus share approvalMoneycontrol.com · 24 Sep, 12:30 pmAbout
About Concord Biotech Limited
Concord Biotech Limited is listed on the NSE under the symbol CONCORDBIO and belongs to the Healthcare sector.
Company details
- Company name
- Concord Biotech Limited
- NSE symbol
- CONCORDBIO
- BSE scrip code
- 543960
- ISIN
- INE338H01029
- Listed on
- NSE, BSE, MSEI
- Series
- EQ (normal equity)
- Listed on NSE since
- 18 Aug 2023
- Face value
- ₹1 per share
- Market lot
- 1 share
- Shares issued
- 10.46 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Miscellaneous Commercial Services
- Managing director / CEO
- Ankur Vaid
- Chair
- Sudhir Jairam Vaid
- Headquarters
- Ahmedabad, Gujarat, India
- Registered address
- B-1601-1602, B-Wing, Mondeal Heights, Iskcon CrossRoad, S. G. Highway, Ahmedabad - 380015, Gujarat
- Founded
- 1984
- Employees
- 1,624
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- concordbiotech.com
Peers
Other Healthcare stocks
-
DIVISLABDivi's Laboratories
₹11,485.00
+1.04%
-
ALKEMAlkem Laboratories
₹5,302.00
-2.68%
-
GRANULESGranules India
₹840.50
+5.16%
-
SUNPHARMASun Pharmaceutical Industries
₹1,885.00
-0.91%
-
LAURUSLABSLaurus Labs
₹2,400.00
-1.19%
-
AUROPHARMAAurobindo Pharma
₹1,807.20
-1.11%
-
ACUTAASAcutaas Chemicals
₹3,996.10
+2.02%
-
APOLLOHOSPApollo Hospitals Enterprise
₹8,515.00
-1.03%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.